These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20470190)

  • 21. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.
    Gagne P; Akalu A; Brooks PC
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to antiangiogenic therapies.
    Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA
    Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?
    Mancuso A; Sternberg CN
    Crit Rev Oncol Hematol; 2005 Jul; 55(1):67-81. PubMed ID: 15890525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-angiogenic therapies for malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA
    Expert Opin Investig Drugs; 2012 Jun; 21(6):833-44. PubMed ID: 22519641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiangiogenic therapy in the management of brain tumors: a clinical overview.
    Kunnakkat S; Mathew M; Narayana A
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):353-63. PubMed ID: 22825032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating endothelial cells as biomarkers in clinical oncology.
    Mancuso P; Bertolini F
    Microvasc Res; 2010 May; 79(3):224-8. PubMed ID: 20176038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Angiogenesis and hematologic malignancy].
    Zini JM; Tobelem G
    Bull Cancer; 2007 Jul; 94 Spec No():S241-6. PubMed ID: 17846010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metronomic dosing of chemotherapy: applications in pediatric oncology.
    Stempak D; Seely D; Baruchel S
    Cancer Invest; 2006; 24(4):432-43. PubMed ID: 16777697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Escape mechanisms after antiangiogenic treatment, or why are the tumors growing again?
    Hlushchuk R; Makanya AN; Djonov V
    Int J Dev Biol; 2011; 55(4-5):563-7. PubMed ID: 21858777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiangiogenesis, anti-VEGF(R) and outlook.
    Petersen I
    Recent Results Cancer Res; 2007; 176():189-99. PubMed ID: 17607926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-angiogenic therapy: adapting strategies to overcome resistant tumors.
    Mitchell DC; Bryan BA
    J Cell Biochem; 2010 Oct; 111(3):543-53. PubMed ID: 20626031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy.
    Pasqualetti G; Danesi R; Del Tacca M; Bocci G
    Pharmacogenomics; 2007 Jan; 8(1):49-66. PubMed ID: 17187509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives.
    Custodio A; Barriuso J; de Castro J; Martínez-Marín V; Moreno V; Rodríguez-Salas N; Feliu J
    Cancer Treat Rev; 2013 Dec; 39(8):908-24. PubMed ID: 23510598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-angiogenic therapy, a new player in the field of sarcoma treatment.
    Versleijen-Jonkers YM; Vlenterie M; van de Luijtgaarden AC; van der Graaf WT
    Crit Rev Oncol Hematol; 2014 Aug; 91(2):172-85. PubMed ID: 24613529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current data on predictive markers for anti-angiogenic therapy in thoracic tumours.
    Reinmuth N; Thomas M; Meister M; Schnabel PA; Kreuter M
    Eur Respir J; 2010 Oct; 36(4):915-24. PubMed ID: 20889462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiangiogenic therapies: going beyond their limits.
    Moserle L; Jiménez-Valerio G; Casanovas O
    Cancer Discov; 2014 Jan; 4(1):31-41. PubMed ID: 24356098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular mechanisms of hypertension and heart failure due to antiangiogenic cancer therapies.
    Rees ML; Khakoo AY
    Heart Fail Clin; 2011 Jul; 7(3):299-311. PubMed ID: 21749882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-6: an angiogenic target in solid tumours.
    Middleton K; Jones J; Lwin Z; Coward JI
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):129-39. PubMed ID: 24029605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiangiogenic drugs for colorectal cancer: exploring new possibilities.
    Ferrarotto R; Hoff PM
    Clin Colorectal Cancer; 2013 Mar; 12(1):1-7. PubMed ID: 22763196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating endothelial cells and their subpopulations: role as predictive biomarkers in antiangiogenic therapy for colorectal cancer.
    Manzoni M; Comolli G; Torchio M; Mazzini G; Danova M
    Clin Colorectal Cancer; 2015 Mar; 14(1):11-7. PubMed ID: 25591800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.